Abstract
Introduction: We propose in this study to analyze the results obtained in the experience of Dar El Amal by comparing the two age groups 45-49 years versus over 50 years. This experience of Dar Al Amal was started in Sfax (Tunisia) in 2004. The project had included women over a period of six and a half years. The target population was all women over the age of 45 years.
Results: In the period of the study, 10 000 women had at least one mammography within the first round in Dar El Amal. The average age was 51.56 years. The recall rate was more important in women aged 45-49 years compared with those over 50 years with a statistically significant relationship (p=0.013). Tests classified ACR0 and ACR3 predominated in women aged between 45 and 49 years with a statistically significant relationship. The positive predictive value (PPV) of mammography was better in those over 50 years (p=0.012).
Conclusion: The majority of countries in the world opt for screening from the age of 50 years. Women under 50 years are not routinely concerned, but they have more right to a targeted and appropriate screening.
Keywords: Screening, mammography, breast cancer.
Reviews on Recent Clinical Trials
Title:A Comparative Study of Breast Cancer Screening by Age Across 10000 Tunisian Women
Volume: 11 Issue: 3
Author(s): Jamel Daoud, Wala Ben Kridis, Fatma Elloumi, Inès Ayedi, Wafa Mnejja, Ouhoud Yaiche and Mounir Frikha
Affiliation:
Keywords: Screening, mammography, breast cancer.
Abstract: Introduction: We propose in this study to analyze the results obtained in the experience of Dar El Amal by comparing the two age groups 45-49 years versus over 50 years. This experience of Dar Al Amal was started in Sfax (Tunisia) in 2004. The project had included women over a period of six and a half years. The target population was all women over the age of 45 years.
Results: In the period of the study, 10 000 women had at least one mammography within the first round in Dar El Amal. The average age was 51.56 years. The recall rate was more important in women aged 45-49 years compared with those over 50 years with a statistically significant relationship (p=0.013). Tests classified ACR0 and ACR3 predominated in women aged between 45 and 49 years with a statistically significant relationship. The positive predictive value (PPV) of mammography was better in those over 50 years (p=0.012).
Conclusion: The majority of countries in the world opt for screening from the age of 50 years. Women under 50 years are not routinely concerned, but they have more right to a targeted and appropriate screening.
Export Options
About this article
Cite this article as:
Daoud Jamel, Kridis Ben Wala, Elloumi Fatma, Ayedi Inès, Mnejja Wafa, Yaiche Ouhoud and Frikha Mounir, A Comparative Study of Breast Cancer Screening by Age Across 10000 Tunisian Women, Reviews on Recent Clinical Trials 2016; 11(3) . https://dx.doi.org/10.2174/1574887111666160502155844
DOI https://dx.doi.org/10.2174/1574887111666160502155844 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structural Requirements of Heparin and Related Molecules to Exert a Multitude of Anti-Inflammatory Activities
Mini-Reviews in Medicinal Chemistry DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer
Current Molecular Medicine Cell Arrest and Apoptosis Induced by the Next Generation of Vanadium Based Drugs: Action Mechanism to Structure Relation and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Role of Membrane Transporters and Metabolizing Enzymes in Ocular Drug Delivery
Current Drug Metabolism In Vitro and In Vivo Models of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Coumarin Compounds in Medicinal Chemistry: Some Important Examples from the Last Years
Current Topics in Medicinal Chemistry TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Current Drug Targets Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Toxicity and Tolerability of <sup>177</sup>Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin – A Phase 2 Registry Study
Current Radiopharmaceuticals Adipose Tissue: Something More than Just Adipocytes
Current Nutrition & Food Science Recent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin
Current Pharmaceutical Design Applications of Induced Pluripotent Stem Cells in the Modeling of Human Inflammatory Bowel Diseases
Current Stem Cell Research & Therapy Chemistry and Theranostic Applications of Radiolabeled Nanoparticles for Cardiovascular, Oncological, and Pulmonary Research
Current Topics in Medicinal Chemistry Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Carbon Nanotubes as an Advanced Drug and Gene Delivery Nanosystem
Current Nanoscience Electromagnetic Energy as a Bridge Between Atomic and Cellular Levels in the Genetics Approach to Cancer Treatment
Current Topics in Medicinal Chemistry Polymorphisms in miRNAs Gene (146a, 149, 196a) and Susceptibility to ARV-associated Hepatotoxicity
Current Genomics ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments
Current Cancer Drug Targets Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil
Clinical Cancer Drugs